A new sleeping pill that increases dreaming sleep improves memory capacity, according to the results of new research.
With only 10% of the 20-30% of the population who suffer with insomnia taking medication, pharmaceutical companies have been searching for the perfect sleeping pill. And one company at least has developed a completely new type of drug that not only induces sleep, but also increases the dream phase, consolidating memory and improving one’s sense of wellbeing.
The drug targets the orexin system, which is also associated with feeding and addiction. Because of this, experts think a drug that effectively targets the system could also find application in treatments for obesity and addiction.
Orexin is a neuropeptide hormone that was discovered in 1998. It is known to control feeding and is associated with narcolepsy, a sleeping disorder that causes people to fall asleep several times a day and to have paralyzing attacks.
Swiss company Actelion’s candidate drug orexin-RA-1 blocks the orexin system. Rats given the drug slept soundly and performed better in maze tests the following day than rats given conventional sleeping medications, suggesting that the drug improves memory capacity. Measurements of muscle tone and brain activity revealed an increase in the dream phase of sleep. ‘The dream phase is when memory is hardwired in the brain,’ Actelion CEO Jean Paul Clozel told Chemistry & Industry.
According to Clozel, older medications reduce REM sleep so that people do not dream enough and wake feeling tired and unwell.
Shahrad Taheri, a lecturer in medicine at the University of Bristol and one of the first people to experiment on orexin, says that a drug acting on this system could have beneficial effects other than inducing sleep.
‘Overweight is associated with obesity, and orexin is thought to be involved in feeding regulation,’ he says. ‘A beneficial effect of blocking the orexin system could be that the person would eat less.’ The fact that narcoleptoics are resistant to amphetamine addiction also suggests an application in preventing addiction, according to Taheri.
The drug is going into Phase II trials. Clozel says it could be on the market by 2012 and admits that there are plans to extend its application beyond insomnia.
Unlike older medicines, orexin-RA-1 shows no sign of being addictive or of losing its effect over time. Attempts by other companies to develop a drug targeting this system failed to reach the clinical trials phase.
Source: Society of Chemical Industry
Related stories:
Researcher transplants stem cells to try to save patients' legs
A Northwestern University Feinberg School of Medicine researcher has launched the first U.S. trial in which a purified form of subjects' own adult stem cells was transplanted into their leg muscles with severely blocked arteries to try to grow new small blood vessels and restore circulation in their legs.
Why Women Get More Migraines Than Men
For every man with a migraine, three women are struck by the severe headaches that often come with nausea, sensitivity to light and sound, and aura. That means a staggering 18 to 25 percent of women suffer from migraines, making it one of the most common disabling conditions faced by women around the globe.
'Wake-Up Pill' Under Study to Treat Patients with Bipolar Disorder
A preliminary study of 85 patients with bipolar disorder shows that a drug used to treat patients with sleep disorders might also control the depressive symptoms associated with bipolar disorder. At least 44 percent of the participants in the study reported improved symptoms, a noteworthy improvement for a disorder in which new treatments are needed, according to the study’s author, Mark Frye, M.D., director of the Mayo Clinic Mood Disorders Clinic and Research Program.
Scientists Spot Mechanism Behind Promising New Sleep Drug
An experimental drug called gaboxadol may soon help millions of bleary-eyed insomniacs get to sleep, and a multi-center team of U.S. scientists believes they've pinpointed just how the drug works.
Violent dreams may hint at why dreaming evolved, researchers say
Twenty years ago, scientists discovered a bizarre disorder whose victims act out their dreams while asleep, often hurting themselves or their spouses in the process.
One patient kicked a hole in his bedroom wall, according to a paper published in a medical journal. Another tried to jump out a window. A third fired an unloaded gun, a fourth attempted to set his bed on fire. Still others tried to choke their wives.
Pill that boosts productivity gaining favor, raising concerns among medical ethicists
In a place like Silicon Valley, where career prospects often hinge on a person's intelligence and ability to work hellishly long hours, "brain doping" probably was inevitable.
1 step back ... 2 steps forward
Women with hormone-receptor positive, metastatic breast cancer may take medications for years to help keep their cancer at bay, but when the tumor becomes resistant to anti-hormonal drugs, treatment with chemotherapy becomes the only option. But a study presented today at the 2008 ASCO Breast Cancer Symposium may change this approach. Early data suggests a new treatment approach can "re-sensitize" the tumor, allowing anti-hormonal drugs to do their job once again.
Research suggests that cigarettes' power may not be in nicotine itself
There may be a very good reason why coffee and cigarettes often seem to go hand in hand. A Kansas State University psychology professor's research suggests that nicotine's power may be in how it enhances other experiences. For a smoker who enjoys drinking coffee, the nicotine may make a cup of joe even better. And that may explain why smoking is so hard to quit.